Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

June 23, 2005 updated by: Theragenics Corporation

A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration

The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This is a multi-center randomized study of three doses of radiation (assigned 1:1:1) delivered by the TheraSight(TM) Brachytherapy System in participants with choroidal neovascularization (CNV) secondary to wet (exudative) AMD. Each participant receives a single dose of radiation delivered by one-time only brachytherapy. Participants are followed for three years after the radiation treatment.

Study Type

Interventional

Enrollment

30

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Georgia
      • Atlanta, Georgia, United States
        • Recruiting
        • Theragenics Clinical Site
      • Augusta, Georgia, United States
        • Recruiting
        • Theragenics Clinical Site
    • Indiana
      • Indianapolis, Indiana, United States
        • Recruiting
        • Theragenics Clinical Site
    • Massachusetts
      • Boston, Massachusetts, United States
        • Recruiting
        • Theragenics Clinical Site
    • New Jersey
      • Newark, New Jersey, United States
        • Recruiting
        • Theragenics Clinical Site
    • North Carolina
      • Raleigh / Durham, North Carolina, United States
        • Recruiting
        • Theragenics Clinical Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 50 years or older.

  • Active primary or recurrent subfoveal CNV secondary to AMD with minimally classic or occult lesion, where an active lesion is defined as one or more of the following:

    a) An increase > 10% in lesion size (greatest linear dimension) on screening fluorescein angiography compared to previous fluorescein angiography no more than 180 days preceding screening visit

    • b) Subretinal hemorrhage associated with CNV within 90 days of screening visit.
    • c) Visual acuity loss > 1 Snellen line in screening visual acuity compared to previous visual acuity no more than 180 days preceding screening
  • Lesion < 6 mm greatest linear dimension (GLD)
  • Submacular blood must comprise less than 75% of the total lesion
  • Subretinal fibrosis must comprise less than 25% of the total lesion
  • Study eye best-corrected vision of 20/100 or poorer measured on an ETDRS chart (< 48 letters correct)
  • Fellow eye best-corrected vision that is at least one line better on an ETDRS chart than the best-corrected vision of the study eye
  • HbA1c < 6%
  • Read and signed informed consent

Exclusion Criteria:

  • Prior AMD therapy treatment, including but not limited to laser and photodynamic therapy.
  • Current or planned participation in the next 180 days in other experimental trials involving treatment of neovascular AMD in the study eye, ocular devices, or trials involving treatment for ocular conditions other than AMD.
  • Prior ophthalmic surgery for the study eye other than cataract extraction and/or capsulotomy. A minimum interval of 180 days must elapse between cataract extraction or capsulotomy and study enrollment.
  • Likely need for cataract surgery in study eye during the 180 days following TheraSight(TM) System treatment.
  • Presence of other eye diseases that could compromise visual acuity in the study eye or that, in the clinical judgment of the evaluating study ophthalmologist, might create special risk for the study participant.
  • CNV due to other causes such as ocular histoplasmosis or pathologic myopia.
  • Endstage fibrotic disciform lesions.
  • Diabetes requiring diet modification, or medication, or insulin.
  • Current history of malignancy (except participants having basal cell carcinoma that was treated successfully, or other malignancy operated on or treated and in remission for five years prior to inclusion in the trial).
  • Hypertensive retinopathy.
  • Major cardiovascular or cerebrovascular event within the last year; examples include congestive heart failure, myocardial infarction, and stroke.
  • Inability to complete follow-up.
  • Allergy to fluorescein dye.
  • Previous radiation to the study eye.
  • Pregnancy at time of surgical procedure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Incidence of serious adverse events 30 to 270 days after treatment

Secondary Outcome Measures

Outcome Measure
Serious adverse events occurring 9 months to 3 years after treatment
Reported adverse events occurring at any time after treatment
Feasibility of device use based on physician interviews and ultrasonography
Observation of retinal and angiographic appearance of CNV lesion and best-corrected visual acuity

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Theragenics Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2004

Study Registration Dates

First Submitted

December 22, 2004

First Submitted That Met QC Criteria

December 22, 2004

First Posted (Estimate)

December 23, 2004

Study Record Updates

Last Update Posted (Estimate)

June 24, 2005

Last Update Submitted That Met QC Criteria

June 23, 2005

Last Verified

January 1, 2005

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NPD-07-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Macular Degeneration

Clinical Trials on Ocular Brachytherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe